Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Meningococcal C naive subjects are required to fulfill all of the following criteria:~* Age ≥ 30 years~* Good health according to the investigator~* Willingness and ability to adhere to the study regimen~* Able to give informed consent~Meningococcal C experienced subjects are required to fulfill all of the following criteria:~* Age ≥ 18 years~* Good health according to the investigator~* Willingness and ability to adhere to the study regimen~* Able to give informed consent~Exclusion Criteria:~Meningococcal C naïve subjects should not have:~* Known previous invasive meningococcal infection~* Known or suspected previous vaccination against meningococcal disease~* Known or suspected allergy against any of the vaccine components~* Close contact in the last 60 days with a person known to be Neisseria positive~* History of unusual or severe reactions to any previous vaccination~* Family history of Guillain-Barré Syndrome~* Known or suspected immune deficiency, either congenital or acquired~* Administration of plasma or blood products less than three months prior to inclusion in the study~* Pregnancy (breastfeeding is allowed)~* Fertile female not conforming to prescribed contraceptive use (await first menstruation after vaccination before getting pregnant)~* Any infectious disease~* Bleeding disorders or use of anticoagulants~* Participation as a subject in another trial in the last 3 months~Meningococcal C experienced subjects should not have:~* Known or suspected allergy against any of the vaccine components~* Known previous vaccination with a quadrivalent meningococcal vaccine (either conjugate or polysaccharide)~* Close contact in the last 60 days with a person known to be Neisseria positive~* History of unusual or severe reactions to any previous vaccination~* Family history of Guillain-Barré Syndrome~* Known or suspected immune deficiency, either congenital or acquired~* Administration of plasma or blood products less than three months prior to inclusion in the study~* Pregnancy (breastfeeding is allowed)~* Fertile female not conforming to prescribed contraceptive use (await first menstruation after vaccination before getting pregnant)~* Any infectious disease~* Bleeding disorders or use of anticoagulants~* Participation as a subject in another trial in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Menveo, dose escalating (Type: EXPERIMENTAL): None
- Nimenrix, dose escalating (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).